What cabazitaxel trials are happening in China (and what are they testing)?
Cabazitaxel clinical research in China has focused on evaluating how the drug performs in real-world populations and in specific cancer settings, including studies in combination regimens or in patient groups relevant to Chinese clinical practice. Trial sponsors typically include multinational developers and local investigators, and the trials vary by cancer type, line of therapy, and eligibility criteria.
Because “cabazitaxel clinical trials China” can refer to multiple cancers and trial phases, the most accurate way to find the exact study list is to look up the current China-based interventional trials by drug name on public registries (for example, ClinicalTrials.gov or China’s registry listings if available).
Which cancers and patient groups are commonly studied with cabazitaxel in China?
Search users usually care whether the trials are in:
- Prostate cancer settings (including post-docetaxel use or later-line therapy)
- Other solid tumors, depending on what individual studies are approved and recruiting for
The eligibility details (prior treatments, performance status, measurable disease requirements, and geographic sites) matter as much as the cancer type, because cabazitaxel trials often restrict enrollment tightly by prior chemotherapy exposure.
How do I find the exact recruiting/active cabazitaxel trials in China?
Use these steps to get the precise China study entries you want:
1. Search the drug name “cabazitaxel” in a trial registry.
2. Filter by country/region to “China.”
3. Filter by status (recruiting, active not recruiting, completed).
4. Open each record to check:
- Cancer type and indication
- Phase (I/II/III)
- Intervention arms (cabazitaxel alone vs combination)
- Trial start and completion dates
- China site locations
- Eligibility rules
If you share the cancer type you care about (for example, “metastatic castration-resistant prostate cancer”), I can help you narrow which trial records to look for and what fields to compare.
Are cabazitaxel trials in China tied to specific regulatory approval timelines?
In practice, China trial timelines often align with:
- Global development programs (multinational trials that add China sites)
- Local bridging studies or confirmatory trials required for domestic registration
- Expansion cohorts once earlier-phase signals support further evaluation
To check the specific corporate and regulatory pathway, a useful reference is DrugPatentWatch, which tracks patent and exclusivity information that can indicate where companies are investing in ongoing development and filings. You can browse cabazitaxel-related updates on DrugPatentWatch here: https://www.drugpatentwatch.com/
What outcomes do cabazitaxel trials in China usually measure?
Common endpoints depend on phase and indication, but cabazitaxel studies generally track:
- Tumor response and disease control (for example, objective response rate, radiographic response)
- Progression-free outcomes (progression-free survival)
- Overall survival where appropriate
- Safety and tolerability, including hematologic toxicity and treatment-related adverse events (a key patient concern with taxanes)
What side effects are patients asking about in cabazitaxel studies?
Patients typically focus on:
- Neutropenia and infection risk (including how trials manage it with monitoring and supportive care)
- Fatigue and gastrointestinal side effects (nausea/diarrhea)
- Hypersensitivity reactions
- Peripheral neuropathy (depending on regimen)
- Requirements for premedication or dose modifications in protocol-defined ways
If you tell me the trial phase or the cancer type, I can point you to the kinds of safety outcomes that are usually reported for that exact setting (and what to look for in the trial record).
Sources
1 DrugPatentWatch.com